Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1992 Jul;216(1):44–54. doi: 10.1097/00000658-199207000-00007

A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Kyoto Research Group for Digestive Organ Surgery.

PMCID: PMC1242545  PMID: 1632701

Abstract

The current study was designed to compare the effects of oral administration of the streptococcal preparation, OK-432, as an adjuvant immunotherapy versus those of intradermal administration of OK-432 on the survival of patients after surgery for gastric cancer. The patients were stratified into two groups after surgery: a curative surgery stratum and a palliative surgery stratum. Then the patients in each stratum were randomly assigned into three groups: an oral placebo group, an oral OK-432 group, and an intradermal OK-432 group. All of the patients were given fluoropyrimidines orally in combination with OK-432 or placebo for 2 years after surgery. A total of 1011 patients were registered between 1982 and 1985, and 970 patients were eligible for statistical analysis. The survival rate of the oral OK-432 group was significantly higher than those of the other two groups after curative surgery. There were no significant difference in the survival rates between the three groups after palliative surgery, however. The effect of oral OK-432 was quite pronounced in patients after curative surgery for stage II to IV gastric cancer, especially in those patients with regional node involvement. Furthermore, it was found that the spleen is necessary for effective immunotherapy with oral OK-432, because the survival rate of the oral OK-432 group was significantly improved in patients whose spleens were preserved, when compared with splenectomized patients. These results demonstrate that oral adjuvant immunotherapy with OK-432 is beneficial after curative surgery for gastric cancer.

Full text

PDF
44

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blake J. R., Hardcastle J. D., Wilson R. G. Gastric cancer: a controlled trial of adjuvant chemotherapy following gastrectomy. Clin Oncol. 1981 Mar;7(1):13–21. [PubMed] [Google Scholar]
  2. Bland P. W., Britton D. C., Richens E. R., Pledger J. V. Peripheral, mucosal, and tumour-infiltrating components of cellular immunity in cancer of the large bowel. Gut. 1981 Sep;22(9):744–751. doi: 10.1136/gut.22.9.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clancy R., Pucci A. Sensitisation of gut-associated lymphoid tissue during oral immunisation. Aust J Exp Biol Med Sci. 1978 Jun;56(3):337–340. doi: 10.1038/icb.1978.36. [DOI] [PubMed] [Google Scholar]
  4. Engstrom P. F., Lavin P. T., Douglass H. O., Jr, Brunner K. W. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer. 1985 May 1;55(9):1868–1873. doi: 10.1002/1097-0142(19850501)55:9<1868::aid-cncr2820550904>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  5. Eriguchi M., Fujii G. Oral administration of BCG as a local immunotherapy of gastrointestinal cancer. J Surg Oncol. 1984 Jun;26(2):100–106. doi: 10.1002/jso.2930260206. [DOI] [PubMed] [Google Scholar]
  6. Guy-Grand D., Griscelli C., Vassalli P. The gut-associated lymphoid system: nature and properties of the large dividing cells. Eur J Immunol. 1974 Jun;4(6):435–443. doi: 10.1002/eji.1830040610. [DOI] [PubMed] [Google Scholar]
  7. Higgins G. A., Amadeo J. H., Smith D. E., Humphrey E. W., Keehn R. J. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer. 1983 Sep 15;52(6):1105–1112. doi: 10.1002/1097-0142(19830915)52:6<1105::aid-cncr2820520629>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  8. Hutchinson G. H., Symes M. O., Williamson R. C. Cytotoxicity of lymphocytes from blood, tumour and regional lymph nodes against K562 cells and autoplastic colorectal tumour cells. Br J Cancer. 1982 Oct;46(4):682–686. doi: 10.1038/bjc.1982.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Imanaga H., Nakazato H. Rseults of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg. 1977 Mar;2(1):213–221. doi: 10.1007/BF01665086. [DOI] [PubMed] [Google Scholar]
  10. Kim J. P. The concept of immunochemosurgery in gastric cancer. World J Surg. 1987 Aug;11(4):465–472. doi: 10.1007/BF01655811. [DOI] [PubMed] [Google Scholar]
  11. Maruyama K., Miwa K., Kinoshita T. [Improvement of Japanese general rules and the TNM classification of stomach cancer--a proposal for a new stage-grouping]. Gan No Rinsho. 1986 Aug;32(10):1357–1361. [PubMed] [Google Scholar]
  12. Mathé G., Amiel J. L., Schwarzenberg L., Schneider M., Cattan A., Schlumberger J. R., Hayat M., De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697–699. doi: 10.1016/s0140-6736(69)92648-8. [DOI] [PubMed] [Google Scholar]
  13. Müller-Schoop J. W., Good R. A. Functional studies of Peyer's patches: evidence for their participation in intestinal immune responses. J Immunol. 1975 Jun;114(6):1757–1760. [PubMed] [Google Scholar]
  14. Nakazato H., Koike A., Ichihashi H., Saji S., Danno M., Ogawa N. [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer]. Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 1):2563–2576. [PubMed] [Google Scholar]
  15. Nio Y., Inamoto T., Hori T., Kan N., Tsuchitani T., Kodama H., Tobe T., Ohgaki K. [The oral administration of OK-432. The 5th report: the effects on the lymphoproliferative response and natural killer cell activity in mice with transplanted cecal tumors]. Nihon Gan Chiryo Gakkai Shi. 1985 Apr 20;20(3):597–608. [PubMed] [Google Scholar]
  16. Nio Y., Ohgaki K., Kan N., Tsuchitani T., Imai S., Okino T., Hori T., Tobe T., Nakamura M., Kodama H. [Oral administration of OK-432 (Picibanil) (7th report). Clinical application: effects on advanced and recurrent cancers]. Nihon Gan Chiryo Gakkai Shi. 1987 Dec 20;22(10):2436–2445. [PubMed] [Google Scholar]
  17. Nio Y., Ohgaki K., Tsuchitani T., Imai S., Shiraishi T., Tobe T. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer. Biotherapy. 1990;2(3):213–222. doi: 10.1007/BF02173522. [DOI] [PubMed] [Google Scholar]
  18. Nio Y., Shiraishi T., Tsuchitani T., Tobe T., Sugawara Y., Saito M., Kamiyama H. Antitumor activity of orally administered streptococcal preparation, OK-432 on murine solid tumors and its absorption from the gut. In Vivo. 1989 Sep-Oct;3(5):307–313. [PubMed] [Google Scholar]
  19. Nio Y., Zighelboim J., Berek J. S., Bonavida B. Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432. Cancer Immunol Immunother. 1988;27(3):246–254. doi: 10.1007/BF00205447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nio Y., Zighelboim J., Berek J., Bonavida B. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer. 1989 Jul 15;64(2):434–441. doi: 10.1002/1097-0142(19890715)64:2<434::aid-cncr2820640216>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  21. Popiela T., Zembala M., Kulig J., Czupryna A., Uracz W. Postoperative immunochemotherapy (BCG + 5-FU) in advanced gastric cancer. Anticancer Res. 1988 Nov-Dec;8(6):1423–1427. [PubMed] [Google Scholar]
  22. Rothberg R. M., Kraft S. C., Michalek S. M. Systemic immunity after local antigenic stimulation of the lymphoid tissue of the gastrointestinal tract. J Immunol. 1973 Dec;111(6):1906–1913. [PubMed] [Google Scholar]
  23. Shiraishi T., Nio Y., Imai S., Tsubono M., Morimoto H., Tseng C. C., Tobe T., Tanaka T., Kitamura O., Sakanashi S. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)]. Nihon Gan Chiryo Gakkai Shi. 1990 Apr 20;25(4):799–811. [PubMed] [Google Scholar]
  24. Shiraishi T., Nio Y., Imai S., Tsubono M., Morimoto H., Tseng C. C., Tobe T., Tanaka T., Kitamura O., Sakanashi S. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)]. Nihon Gan Chiryo Gakkai Shi. 1990 May 20;25(5):997–1012. [PubMed] [Google Scholar]
  25. Taguchi T., Furue H., Kimura T., Kondo T., Hattori T., Itoh I., Ogawa N. [Results of phase III study of lentinan]. Gan To Kagaku Ryoho. 1985 Feb;12(2):366–378. [PubMed] [Google Scholar]
  26. Tsuchitani T., Kodama H., Tobe T., Nio Y., Kan N., Inamoto T., Ohgaki K. [Experimental study of oral administration of streptococcal preparation "OK-432". The 6th report: its effect on in vivo anti-tumor immunity of the mice with transplanted cecal tumor]. Nihon Gan Chiryo Gakkai Shi. 1985 Apr 20;20(3):609–617. [PubMed] [Google Scholar]
  27. Uchida A., Hoshino T. Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer. 1980 Feb;45(3):476–483. doi: 10.1002/1097-0142(19800201)45:3<476::aid-cncr2820450311>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES